Condition: Myeloid Malignancy · Sponsor: Henry Ford Health System
Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD
This description comes directly from the study's public registry record.
shatha farhan, MD · 313 916 5002 · SFARHAN1@HFHS.ORG
NALINI JANAKIRAMAN, MD
Always discuss trial participation with your own doctor first.
| Henry ford hospital | Detroit, Michigan, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03850418